SEP 30, 2015 12:00 PM PDT

Keynote Presentation: What's New in Robotics and minimally invasive therapy for prostate cancer and prostate disease

Speakers
  • Chief of Urology at Crouse Hospital and Medical Director for Associated Medical Professionals
    Biography
      Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor to full Professor in Urology and Radiology in eight years. After 10 years, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has over 150 publications in peer-reviewed journals and has authored three textbooks in endourology and one in general urology. He serves on the editorial board for the Journal of Robotic Surgery, Journal of Endourology, Current Opinions in Urology and Urology Index and Reviews. He serves as a reviewer for eight surgical journals.

      At the present time he is Chief of Urology at Crouse Hospital in Syracuse, New York and Medical Director for Associated Medical Professionals. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urological surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH) and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and 23 states. He has trained 16 fellows in endourology and advanced robotic surgery.

      In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.
    • Urologist, NYU Langone Medical Center
      Biography
        Herbert Lepor, MD, is one of the leading experts in the field of prostate cancer. He is currently the Martin Spatz Chairman of the Department of Urology and the Director of the Smilow Comprehensive Prostate Cancer Center at the NYU Langone Medical Center in New York. He was previously appointed Chairman of Urology at NYU School of Medicine at the age of 37, the youngest chairman of a major academic urology department in the country at that time. Dr. Lepor has written more than 300 articles on the topic of prostate cancer in peer-reviewed academic publications. He has made important contributions to the screening, detection, and treatment of prostate cancer.

      Abstract

      This presentation discusses the advantages and disadvantages of robotic surgery. The initial goals for a robotic prostatectomy will be discussed as well as patient expectations and outcomes.  Robotic surgery has been shown to have achieved good outcomes with regards to pain, incision size, and recovery times.  In addition, the blood loss is significantly less when compared to open surgery. Perioperative outcomes, oncologic outcomes (surgical margins and biochemical recurrence rate) as well as functional outcomes (potency and continence) will be detailed.  
       


      Show Resources
      You May Also Like
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      SEP 03, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 03, 2020 9:00 AM PDT
      DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
      C.E. CREDITS
      This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      JUN 17, 2020 1:30 PM PDT
      C.E. CREDITS
      JUN 17, 2020 1:30 PM PDT
      Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
      NOV 05, 2020 7:00 AM PST
      C.E. CREDITS
      NOV 05, 2020 7:00 AM PST
      DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
      Loading Comments...
      Show Resources